This article is more than 5 years old. Information may no longer be current.

Enrollment complete in Allegro's phase 2b trial of Luminate

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The last patient has been enrolled in Allegro Ophthalmics’ phase 2b trial of Luminate for inducing posterior vitreous detachment in patients with nonproliferative diabetic retinopathy, according to a company press release.

Intravitreal injections of Luminate (ALG-1001), an integrin peptide therapy, will be studied in 100 patients in the double-masked, placebo-controlled, dose-ranging PACIFIC trial, the release said. Patients will be randomized to receive 1 mg, 2 mg, 3 mg or 4 mg of the treatment drug or a balanced salt solution.

“There are currently no practical treatment options available for PVD induction in nonproliferative DR, resulting in a significant need for novel, nonsurgical treatments that optimize long-term clinical outcomes,” Vicken Karageozian, MD, president and chief medical officer of Allegro Ophthalmics, said in the release. “We are optimistic that Luminate will continue to show efficacy and provide meaningful therapeutic benefit to patients with diabetic retinopathy and other vitreoretinal diseases.”